Decellularized adipose biomaterial and method for preparing same
Through multi-step processing and freeze-drying of adipose tissue, cells-free adicellular adicellular biological materials were prepared, which solved the problem of the removal of active protein factors during the decellularization process in the prior art, and achieved sustained release of active proteins and Tissue repair, with high biosafety and long-term preservation capabilities.
Patent Information
- Application Number
- PCT/CN2024/090990
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-07
AI Technical Summary
The prior art is difficult to maintain the biological activity of active protein factors when removing cellular substances and viruses from adipose tissue, affecting the ability of tissue repair and regeneration.
Through a multi-step process, including rinsing, centrifugation, emulsification, filtration, disinfection, decellularization and degreasing treatment, cell-free adipose decellularized biological material is prepared, retaining the active protein factor of the human tissue itself, and lyophilized by freeze-drying The formation of porous structures enhances the biosafety and storage of the material.
This method effectively retains the activity of fat active proteins, achieves sustained release of active proteins in damaged tissues, promotes angiogenesis and tissue repair in the trauma site for a long time, and has good biocompatibility and long-term preservation ability.
Smart Images

Figure CN2024090990_07112024_PF_FP_ABST
Abstract
Description
A kind of fat decellularized biomaterial and preparation method thereof Technical Field
[0001] The present invention relates to the field of biomedical materials, and in particular to a fat decellularized biomaterial and a preparation method thereof. Background Art
[0002] Autologous tissue transplantation is generally considered the gold standard for tissue repair, but it has certain limitations due to limited availability and the risk of secondary damage to the patient. The optimal scaffold for tissue repair is the extracellular matrix of the target tissue. Commercially available allogeneic extracellular matrix products primarily consist of dermis, tendon, nerve, and bone tissue. Compared to xenogeneic materials, human tissue is extremely valuable and typically comes from cadaver donation programs.
[0003] During liposuction surgery, a large amount of adipose tissue is often discarded as medical waste. Studies have shown that adipose decellularized matrix extracted from fat can be used for in vitro adipose tissue engineering and in vivo adipose tissue regeneration. This is not limited to adipose tissue engineering, but also has potential applications in wound healing, bone regeneration, supporting breast tissue reconstruction, and promoting nerve repair.
[0004] Although much progress has been made in research in this field, there are still many problems that need to be solved and studied in depth.
[0005] Commercial decellularized products have very high requirements for viral inactivation and immunogenicity clearance. However, the current complex process of removing cellular material and fat from adipose tissue, and clearing viruses and other immunogenic substances, will also remove active protein factors during decellularization, greatly reducing the inherent biological activity of the adipose decellularized product, thereby affecting the material's ability to guide tissue repair and regeneration.
[0006] Therefore, it is necessary to provide a new adipose decellularized biomaterial and a preparation method thereof to address the deficiencies of the existing technology.
[0007] Summary of the Invention
[0008] The purpose of the present invention is to provide a fat decellularized biomaterial and a preparation method thereof, in particular to provide a biomaterial with the ability to repair tissue and guide tissue regeneration and a preparation method thereof, which can be used in the fields of soft tissue defect repair, plastic surgery and filling.
[0009] In a first aspect of the present invention, a fat-decellularized biomaterial is provided. The fat-decellularized biomaterial is prepared by the following method, which comprises the following steps:
[0010] (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue;
[0011] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;
[0012] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;
[0013] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;
[0014] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C;
[0015] (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization, and defatting to obtain a cell-free fat extract D;
[0016] (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.
[0017] In another preferred embodiment, the post-processed adipose decellularized biological material is a solid material.
[0018] In another preferred embodiment, the post-processed adipose decellularized biomaterial is a block material.
[0019] In another preferred embodiment, the adipose decellularized biomaterial is a porous material.
[0020] In another preferred embodiment, the pore size of the adipose decellularized biomaterial is 1-1000 μm.
[0021] In another preferred embodiment, the adipose decellularized biological material does not contain cells and does not contain fat droplets.
[0022] In another preferred embodiment, the lipid droplets are oil droplets released after the adipocytes are broken.
[0023] In another preferred embodiment, the “does not contain fat droplets” means that in the adipose decellularized biological material, the volume of oil droplets accounts for less than 1% of the total liquid, preferably less than 0.5%, and more preferably less than 0.1%.
[0024] In another preferred embodiment, the cells are selected from the group consisting of endothelial cells, adipose stem cells, macrophages, and stromal cells.
[0025] In another preferred embodiment, the “cell-free” refers to that the average number of cells in 1 ml of adipose decellularized biological material is ≤1, preferably ≤0.5, more preferably ≤0.1, or 0.
[0026] In another preferred embodiment, in step (1), physiological saline is used for rinsing.
[0027] In another preferred embodiment, in the step (2), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.
[0028] In another preferred embodiment, in the step (2), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.
[0029] In another preferred embodiment, in the step (2), the centrifugation is performed at 0-10°C, preferably at 2-5°C, such as 4°C.
[0030] In another preferred embodiment, in the step (2), the intermediate layer is a fat layer containing fat cells.
[0031] In another preferred embodiment, in the step (2), the layered mixture is divided into three layers, the upper layer is an oil layer, the middle layer is a fat layer containing fat cells, and the lower layer is a water layer.
[0032] In another preferred embodiment, in the step (3), the emulsification is mechanical emulsification.
[0033] In another preferred embodiment, the mechanical emulsification is performed by repeatedly blowing with a syringe (such as blowing 20-200 times, preferably 20-150 times, more preferably 20-100 times, and more preferably 30-50 times).
[0034] In another preferred embodiment, the blowing method is to connect two 10 ml injection syringes to a three-way pipe and push and blow repeatedly at a uniform speed.
[0035] In another preferred embodiment, in the step (3), the emulsification includes breaking up and emulsifying by a tissue homogenizer.
[0036] In another preferred embodiment, in the step (3), the rotation speed of the homogenizer is 5000-15000 r / min, preferably 8000-15000 r / min, such as 10000 r / min, 12000 r / min.
[0037] In another preferred embodiment, in the step (3), the emulsification time is 0.5-15 min, preferably 1-10 min, more preferably 1-8 min, most preferably 1-5 min, for example 3 min.
[0038] In another preferred embodiment, in the step (4), before the emulsified fat mixture is subjected to centrifugal treatment, the step further includes freezing and then thawing the emulsified fat mixture.
[0039] In another preferred embodiment, after the freezing and thawing treatment, the thawed mixture is used for centrifugation.
[0040] In another preferred embodiment, the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, and more preferably -70°C to -90°C.
[0041] In another preferred embodiment, the thawing temperature is 20-40°C, preferably 25-40°C, and more preferably 37°C.
[0042] In another preferred embodiment, the thawing is carried out in a water bath at 20-40°C (preferably 25-40°C, more preferably 37°C).
[0043] In another preferred embodiment, the number of cycles of freezing and thawing is 1-5 times (preferably 1, 2, 3 or 4 times).
[0044] In another preferred embodiment, in the step (4), after centrifugation, the emulsified fat mixture is separated into four layers, the first layer being an oil layer, the second layer being a residual fat tissue layer, the third layer being a liquid layer, and the fourth layer being a cell / tissue fragment sedimentation layer.
[0045] In another preferred embodiment, the intermediate solid layer in step (4) is the second layer, namely the residual fat tissue layer.
[0046] In another preferred embodiment, the intermediate liquid layer in step (4) is the third layer, namely the liquid layer.
[0047] In another preferred embodiment, in the step (4), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.
[0048] In another preferred embodiment, in the step (4), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 2-8 min, and most preferably 3-7 min.
[0049] In another preferred embodiment, in the step (4), the centrifugation is performed at 0-10°C, preferably at 2-5°C, such as 4°C.
[0050] In another preferred embodiment, in the step (4), the first layer, the second layer, the third layer and the fourth layer are arranged in sequence from top to bottom.
[0051] In another preferred embodiment, in the step (4), the intermediate liquid layer is a transparent or substantially transparent layer.
[0052] In another preferred embodiment, in the step (4), the intermediate solid layer is yellow or brown.
[0053] In another preferred embodiment, in the step (5), the filtration removes the fat cells or other living cells that may be mixed in the primary fat extract A.
[0054] In another preferred embodiment, in the step (5), the filtration and sterilization are performed using a filter.
[0055] In another preferred embodiment, the filter is a microporous membrane filter.
[0056] In another preferred embodiment, the pore size of the microporous membrane filter is 0.05-0.8 μm, preferably 0.1-0.5 μm, more preferably 0.1-0.4 μm, more preferably 0.15-0.3 μm, more preferably 0.2-0.25 μm, and most preferably 0.22 μm.
[0057] In another preferred embodiment, in the step (5), the filtration and sterilization include first passing through a first filter that can filter out cells, and then passing through a second filter (such as a 0.22 μm filter) that can filter out pathogens (such as bacteria).
[0058] In another preferred embodiment, the step (5) further comprises packaging the fat extract C to form a packaged mixture.
[0059] In another preferred embodiment, the packaged extract is frozen or stored at low temperature.
[0060] In another preferred embodiment, the packaged extract is frozen and stored at -20°C for use. Preferably, the packaged extract is directly used after being frozen and thawed at low temperature (such as -4°C) or room temperature, or is thawed and stored at low temperature (such as 4°C) for a period of time before use.
[0061] In another preferred embodiment, the step (6) includes:
[0062] (6a) emulsifying the primary fat extract B and post-processing it to obtain a solid content;
[0063] (6b) sterilizing the solid contents obtained in step (6a) and post-treating the solid contents;
[0064] (6c) decellularizing the solid contents obtained in step (6b) and performing post-processing to obtain solid contents;
[0065] (6d) defatting the solid contents obtained in step (6c) and post-treating the solid contents;
[0066] (6e) diluting the solid content obtained in step (6d) to obtain a cell-free fat extract D.
[0067] In another preferred embodiment, in step (6) or step (6a), the emulsification treatment includes mechanical emulsification.
[0068] In another preferred embodiment, in step (6) or step (6a), the emulsification treatment includes homogenization and emulsification using a homogenizer.
[0069] In another preferred embodiment, the rotation speed of the homogenizer is 5000-15000 r / min, preferably 8000-15000 r / min, such as 10000 r / min, 12000 r / min.
[0070] In another preferred embodiment, in step (6) or step (6a), the emulsification time is 0.5-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.
[0071] In another preferred embodiment, in the step (6), the emulsification treatment further comprises the step of centrifugally separating the oil layer.
[0072] In another preferred embodiment, the centrifugation is performed at 1000-8000 r / min, preferably 2000-5000 r / min, more preferably 4000 r / min.
[0073] In another preferred embodiment, the centrifugation time is 2-20 min, preferably 5-15 min, more preferably 10 min.
[0074] In another preferred embodiment, in the step (6), after the emulsification treatment, the step of centrifugally separating the oil layer to obtain solid contents is further included.
[0075] In another preferred embodiment, the step (6a) comprises: homogenizing and mechanically emulsifying the primary fat extract B, and separating the oil layer after centrifugation to obtain solid contents.
[0076] In another preferred embodiment, in step (6) or step (6b), the disinfection treatment includes the step of mixing with a disinfectant for disinfection.
[0077] In another preferred embodiment, the mixing includes stirring and shaking.
[0078] In another preferred embodiment, in step (6) or step (6b), the disinfection treatment includes mixing with a disinfectant, and discarding the liquid layer after shaking.
[0079] In another preferred embodiment, in step (6) or step (6b), the disinfection treatment includes irradiation disinfection, and the liquid layer is discarded after the oscillation treatment.
[0080] In another preferred embodiment, the disinfectant is a mixed solution of peracetic acid and ethanol, or supercritical carbon dioxide.
[0081] In another preferred embodiment, the concentration of the peracetic acid is 0.05-3%, preferably 0.1-2%, more preferably 0.1-1%, such as 0.5%.
[0082] In another preferred embodiment, the concentration of ethanol is 1-24%, preferably 2-20%, more preferably 2-10%, such as 4%, 5%, or 8%.
[0083] In another preferred embodiment, the mass ratio of the solid content obtained after emulsification to the disinfectant is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, for example 1:8, 1:10.
[0084] In another preferred embodiment, the shaking treatment time is 0.5-6 h, preferably 1-6 h, such as 4 h.
[0085] In another preferred embodiment, the step (6) or step (6b) includes: after the disinfection treatment, a post-treatment step of rinsing the obtained solid contents.
[0086] In another preferred embodiment, the rinsing includes shaking washing with PBS solution and / or shaking washing with purified water.
[0087] In another preferred embodiment, the step (6b) comprises: mixing the solid contents obtained in step (6a) with a disinfectant, discarding the liquid layer and rinsing to obtain the solid contents.
[0088] In another preferred embodiment, in step (6) or step (6c), the decellularization treatment includes a step of mixing with a decellularization agent.
[0089] In another preferred embodiment, the mixing includes stirring or shaking.
[0090] In another preferred embodiment, in step (6) or step (6c), the decellularization treatment includes mixing with a decellularization agent, and discarding the liquid layer after oscillation treatment.
[0091] In another preferred embodiment, the decellularization agent is selected from SDS, TritonX-100, sodium deoxycholate, or a combination thereof.
[0092] In another preferred embodiment, the concentration of the decellularizing agent is 0.2-5%, preferably 0.5-2%, more preferably 0.8-1.5%, for example 1%.
[0093] In another preferred embodiment, the mass ratio of the solid content obtained after disinfection to the decellularizing agent is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, for example 1:8 or 1:10.
[0094] In another preferred embodiment, the oscillation treatment time is 12-96 hours, such as 12 hours, 24 hours, 48 hours, or 72 hours.
[0095] In another preferred embodiment, the step (6) or step (6c) includes: after the decellularization treatment, a post-treatment step of rinsing the obtained solid contents.
[0096] In another preferred embodiment, the rinsing includes shaking washing with PBS solution and / or shaking washing with purified water.
[0097] In another preferred embodiment, the step (6c) comprises: mixing the solid contents obtained in step (6b) with a decellularizing agent, discarding the liquid layer, and rinsing to obtain the solid contents.
[0098] In another preferred embodiment, in step (6) or step (6d), the degreasing treatment includes the step of mixing with a degreasing agent.
[0099] In another preferred embodiment, the mixing includes stirring or shaking.
[0100] In another preferred embodiment, in step (6) or step (6d), the degreasing treatment includes mixing with a degreasing agent, and discarding the liquid layer after shaking.
[0101] In another preferred embodiment, the degreasing agent is selected from isopropyl alcohol, ethanol, ether, or a combination thereof.
[0102] In another preferred embodiment, the mass ratio of the solid content obtained after decellularization to the degreasing agent is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, for example 1:6, 1:8, or 1:10.
[0103] In another preferred embodiment, the oscillation treatment time is 0.5-24 h, preferably 2-16 h, such as 3 h, 4 h, 8 h.
[0104] In another preferred embodiment, the step (6) or step (6d) includes: after the degreasing treatment, it also includes a post-processing step of rinsing the obtained solid content.
[0105] In another preferred embodiment, the rinsing includes shaking washing with PBS solution and / or shaking washing with purified water.
[0106] In another preferred embodiment, the step (6d) comprises: mixing the solid contents obtained in step (6c) with a degreasing agent, discarding the liquid layer and rinsing to obtain the solid contents.
[0107] In another preferred embodiment, the emulsification treatment, disinfection treatment, decellularization treatment and defatting treatment optionally further include a post-treatment step of washing.
[0108] In another preferred embodiment, the cleaning comprises sequentially cleaning with a PBS solution and cleaning with purified water.
[0109] In another preferred embodiment, the step (6e) comprises: mixing the solid content obtained in step (6d) with a diluent to obtain a cell-free fat extract D.
[0110] In another preferred embodiment, in step (6e), the diluent is water or PBS solution.
[0111] In another preferred embodiment, in step (6e), the mass ratio of the solid content obtained in step (6d) to the diluent is 1:5 to 1:50, preferably 1:10 to 1:50, more preferably 1:10 to 1:30, for example 1:20.
[0112] In another preferred embodiment, in the step (6e), the mixing refers to stirring or shaking to form a uniform emulsion.
[0113] In another preferred embodiment, the step (7) includes the following steps:
[0114] (7a) providing a cell-free fat extract D in the form of an emulsion;
[0115] (7b) adding the fat extract C to the emulsion obtained in step (7a) and mixing;
[0116] (7c) The adipose decellularized biomaterial is obtained after freeze-drying.
[0117] In another preferred embodiment, in the step (7b), the mass ratio of the fat extract C to the emulsion obtained in the step (7a) is 0.01-100:0.01-100, preferably 0.1-10:0.1-10.
[0118] In another preferred embodiment, the step (7c) further includes the steps of first injecting into a mold and then freeze-drying.
[0119] In another preferred embodiment, in the step (7c), the freeze-drying includes the steps of pre-freezing and then freeze-drying.
[0120] In another preferred embodiment, in the step (7c), the freeze-drying comprises the steps of pre-freezing at -50 to -150°C for 12 to 24 hours, and then freeze-drying for 24 to 48 hours.
[0121] In another preferred embodiment, the adipose decellularized biomaterial has one or more characteristics selected from the following group:
[0122] (1) After 2 weeks of in vivo filling, the mass retention rate is greater than 68%, preferably greater than 70%, and more preferably greater than 75%;
[0123] (2) After 2 weeks of filling into the body, the volume retention rate is greater than 70%, preferably greater than 72%, more preferably greater than 75%, and even more preferably greater than 80%;
[0124] (3) Three months after implantation, the mass retention rate is greater than 35%, preferably greater than 37%, and more preferably greater than 40%;
[0125] (4) Three months after implantation, the volume retention rate is greater than 40%, preferably greater than 41%, and more preferably greater than 44%;
[0126] (5) After being placed at 37°C for 14 days, the protein release amount of the extract exceeds 15 μg / mL, preferably exceeds 17 μg / mL.
[0127] In a second aspect of the present invention, a method for preparing the adipose decellularized biomaterial according to the first aspect of the present invention is provided, the method comprising the following steps:
[0128] (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue;
[0129] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;
[0130] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;
[0131] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;
[0132] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C;
[0133] (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization, and defatting to obtain a cell-free fat extract D;
[0134] (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.
[0135] In another preferred embodiment, the method is as described in the first aspect of the present invention.
[0136] In a third aspect of the present invention, a medical material is provided, comprising: the adipose decellularized biomaterial according to the first aspect of the present invention, and a pharmaceutically acceptable carrier.
[0137] In a fourth aspect of the present invention, a medical cosmetic material is provided, comprising: the adipose decellularized biomaterial as described in the first aspect of the present invention, and an acceptable carrier in the field of medical cosmetics.
[0138] In a fifth aspect of the present invention, a tissue repair material is provided, wherein the tissue repair material comprises the adipose decellularized biomaterial according to the first aspect of the present invention.
[0139] In another preferred embodiment, the tissue repair material is an injectable tissue repair material.
[0140] In another preferred embodiment, the tissue repair material further comprises an acceptable carrier.
[0141] In another preferred embodiment, the tissue repair material further comprises a flow agent selected from the group consisting of physiological saline, PBS buffer, glycerol, polyethylene glycol, or a combination thereof.
[0142] In another preferred embodiment, the tissue repair material is applied to the site requiring tissue repair by injection or direct filling of a surgical opening.
[0143] In the sixth aspect of the present invention, there is provided a use of the adipose decellularized biomaterial as described in the first aspect of the present invention for preparing a medical material or a medical cosmetic material, wherein the medical material is used for soft tissue repair and the medical cosmetic material is used for plastic surgery filling.
[0144] In another preferred embodiment, the soft tissue repair comprises one or more features selected from the following group:
[0145] (1) Promote fibroblast proliferation;
[0146] (2) promoting collagen fiber proliferation; and / or
[0147] (3) Promote the regeneration of fat cells. In another preferred embodiment, the plastic surgery filling includes one or more features selected from the following group:
[0148] (1) Promote fibroblast proliferation;
[0149] (2) promoting collagen fiber proliferation; and / or
[0150] (3) Promote the regeneration of fat cells.
[0151] In a seventh aspect of the present invention, a method for soft tissue repair is provided, comprising administering the adipose decellularized biomaterial according to the first aspect of the present invention to a subject in need thereof.
[0152] In another preferred embodiment, the adipose decellularized biomaterial is administered by injection, oral administration, or external application.
[0153] In another preferred embodiment, the injection includes subcutaneous injection, intradermal injection, and intravenous injection.
[0154] In an eighth aspect of the present invention, a method for plastic surgery and filling is provided, the method comprising administering the adipose decellularized biomaterial according to the first aspect of the present invention to a subject in need thereof.
[0155] In another preferred embodiment, the adipose decellularized biomaterial is administered by injection, oral administration, or external application.
[0156] In another preferred embodiment, the injection includes subcutaneous injection, intradermal injection, and intravenous injection.
[0157] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION
[0158] After extensive and in-depth research, the inventors have discovered for the first time a cell-free adipose-derived biomaterial rich in a mixture of active adipose proteins. This biomaterial retains the active protein factors of human tissue, resulting in greater activity and biosafety than recombinant active protein factors. The active proteins are evenly dispersed throughout the biomaterial, enabling sustained release of the active proteins in damaged tissue areas, resulting in a highly effective and long-lasting repair effect, thereby precisely promoting angiogenesis at the site of injury. Furthermore, the freeze-dried biomaterial possesses a porous structure, promoting rapid tissue repair and enabling long-term storage. This is the basis for the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0159] Figure 1 shows the solid contents obtained in step (b4) of Example 1 of the present invention. (The left side is treated with ether, and the right side is treated with isopropanol)
[0160] FIG2 is a diagram of the material histological evaluation of the animal experiment of the present invention, showing the degradation and cell proliferation promotion of Examples 1 and 2 and Comparative Examples 2 and 3.
[0161] the term
[0162] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0163] As used herein, the terms "comprise," "include," and "contain" are used interchangeably to include not only closed definitions but also semi-closed and open definitions. In other words, the terms include "consisting of," "consisting essentially of."
[0164] As used herein, when used in reference to a specific recited value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0165] In the present invention, the term "room temperature" refers to 10-40°C.
[0166] Adipose decellularized biomaterials
[0167] As used herein, the terms "adipose decellularized biomaterial," "biomaterial of the present invention," etc. are used interchangeably and refer to the adipose decellularized biomaterial prepared by mixing a cell-free fat extract solution in a fat mixture obtained by washing and crushing adipose tissue and a cell-free fat extract solid obtained by decellularizing and defatting the fat mixture.
[0168] The biomaterial of the present invention includes acellular fat extract without added components (ie, acellular fat extract C, CEFFE) and adipose decellularized matrix (ie, acellular fat extract D).
[0169] The cell-free fat extract refers to an extract (or extracting liquid) obtained by filtering and sterilizing the intermediate cell-free liquid obtained after emulsified fat separation, after removing residual oil, adipose tissue, and cell / tissue debris precipitation. The cell-free fat extract contains various growth factors, such as insulin-like growth factor 1, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, basic fibroblast growth factor, vascular endothelial growth factor, transforming growth factor-β, hepatocyte growth factor, and platelet-derived growth factor.
[0170] The adipose-derived matrix (ADM) is an extract obtained by further emulsifying, disinfecting, decellularizing, and defatting the cell / tissue fragments precipitated after emulsified fat separation. It contains macromolecular collagen, glycosaminoglycans, elastin, laminin, fibronectin, and other substances, which are themselves excellent tissue repair materials and can also serve as a sustained-release carrier for CEFFE.
[0171] The biomaterial of the present invention is a solid block material. The active protein is evenly dispersed in the matrix or carrier of the biomaterial through a process, has an excellent sustained-release effect, and can be injected into the area requiring tissue repair and / or plastic filling, with a long-lasting repair effect.
[0172] The biomaterial of the present invention is a fat extract without added ingredients, and is an extract derived from adipose tissue prepared without adding any solution, solvent, small molecule, chemical agent, or biological additive during the preparation process (except for the rinsing step).
[0173] A typical method for preparing the biomaterial of the present invention is as described in the second aspect of the present invention. Furthermore, it should be understood that, while it is not necessary to add any additives (or additional ingredients) during the preparation of the biomaterial of the present invention, some or a small amount of safe substances (such as a small amount of water, PBS buffer, physiological saline, etc.) that do not negatively or adversely affect the activity of the extract of the present invention may be added.
[0174] Preparation method of fat decellularized biomaterial
[0175] The present invention provides a method for preparing a cell-free fat biomaterial, comprising the following steps:
[0176] (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing it (e.g., with physiological saline) to obtain rinsed fat tissue;
[0177] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;
[0178] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;
[0179] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;
[0180] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract solution C;
[0181] (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization, and defatting, thereby obtaining a cell-free fat extract solid D;
[0182] (7) The cell-free fat extract C is mixed with D, and then freeze-dried and sterilized to obtain the final adipose decellularized biomaterial E.
[0183] As the preferred technical solution:
[0184] In another preferred embodiment, in the step (2), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.
[0185] In another preferred embodiment, in the step (2), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.
[0186] In another preferred embodiment, the centrifugation temperature is 2-6°C.
[0187] In another preferred embodiment, in the step (3), the emulsification is mechanical emulsification.
[0188] In another preferred embodiment, the mechanical emulsification is performed by repeatedly blowing with a syringe (such as blowing 20-200 times, preferably 20-150 times, more preferably 20-100 times, and more preferably 30-50 times).
[0189] In another preferred embodiment, the blowing method is to connect two 10 ml injection syringes to a three-way pipe and push and blow repeatedly at a uniform speed.
[0190] In another preferred embodiment, in the step (3), the emulsification is performed by a tissue homogenizer.
[0191] In another preferred embodiment, in the step (4), before the emulsified fat mixture is subjected to centrifugal treatment, the step further includes freezing and then thawing the emulsified fat mixture.
[0192] In another preferred embodiment, after the freezing and thawing treatment, the thawed mixture is used for centrifugation.
[0193] In another preferred embodiment, the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, and more preferably -70°C to -90°C.
[0194] In another preferred embodiment, the thawing temperature is 20-40°C, preferably 25-40°C, and more preferably 37°C.
[0195] In another preferred embodiment, the number of cycles of freezing and thawing is 1-5 times (preferably 1, 2, 3 or 4 times).
[0196] In another preferred embodiment, in the step (4), after centrifugation, the emulsified fat mixture is divided into four layers, the first layer is an oil layer, the second layer is a residual fat tissue layer, the third layer is a liquid layer (i.e., an intermediate liquid layer), and the fourth layer is a cell / tissue fragment precipitation layer.
[0197] In another preferred embodiment, in the step (4), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.
[0198] In another preferred embodiment, in the step (4), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 2-8 min, and most preferably 3-7 min.
[0199] In another preferred embodiment, the centrifugation temperature is 2-6°C.
[0200] In another preferred embodiment, in the step (4), the first layer, the second layer, the third layer and the fourth layer are arranged in sequence from top to bottom.
[0201] In another preferred embodiment, in the step (4), the intermediate liquid layer is a transparent or substantially transparent layer, and the intermediate solid layer is yellow or brown.
[0202] In another preferred embodiment, in the step (5), the filtration is capable of removing fat cells from the primary fat extract.
[0203] In another preferred embodiment, in the step (5), the filtration and sterilization are performed through a filter (such as a 0.22 μm microporous filter membrane).
[0204] In another preferred embodiment, the filter is a microporous membrane filter.
[0205] In another preferred embodiment, the pore size of the microporous filter membrane is 0.05-0.8 μm, preferably 0.1-0.5 μm, more preferably 0.1-0.4 μm, more preferably 0.15-0.3 μm, more preferably 0.2-0.25 μm, and most preferably 0.22 μm.
[0206] In another preferred embodiment, in the step (5), the filtration and sterilization are first performed through a first filter that can filter out cells, and then through a second filter (such as a 0.22 μm filter) that can filter out pathogens (such as bacteria).
[0207] In another preferred embodiment, step (5) further comprises packaging the fat extract to form packaged products. (The packaged extract can be stored at -20°C for future use; can be thawed at low temperature (e.g., -4°C) or room temperature and used directly, or can be thawed and stored at low temperature (e.g., 4°C) for a period of time before use).
[0208] Furthermore, in step (6), the method of emulsifying the primary fat extract B is preferably to perform mechanical emulsification using a homogenizer and centrifuge to separate the oil layer, the emulsification speed is preferably 5000-15000 r / min, the emulsification time is preferably 0.5-5 min, the centrifugal speed is preferably 2000-5000 r / min, and the centrifugal time is preferably 5-15 min.
[0209] Furthermore, the solvent used for disinfection treatment is a peracetic acid / ethanol mixed solution, the concentration of peracetic acid is preferably 0.1-3%, the concentration of ethanol is preferably 4-24%, the mass ratio of the contents to the peracetic acid / ethanol mixed solution is preferably 1:2-1:20, the treatment time is preferably 1-6 hours, and the liquid layer is discarded after treatment, and PBS solution washing and purified water washing are carried out in sequence.
[0210] Furthermore, the decellularizing agent is preferably SDS, TritonX-100 and sodium deoxycholate, the decellularizing agent concentration is preferably 0.5-5%, the mass ratio of the contents and the decellularizing agent solution is preferably 1:2-1:20, the treatment time is preferably 12h-72h, and after treatment, the liquid layer is discarded and washed with PBS solution and purified water in sequence.
[0211] Furthermore, the degreasing agent is preferably isopropanol, ethanol, or ether, the mass ratio of the contents to the decellularizing agent solution is preferably 1:2-1:10, the treatment time is preferably 2h-8h, and after treatment, the liquid layer is discarded and washed with PBS solution and purified water in sequence.
[0212] Furthermore, the effect of removing impurities can be adjusted by adjusting the mass ratio of the solid content to the reagents in each step, or the treatment time.
[0213] Furthermore, in step (7), the cell-free fat extract C and D are mixed as follows:
[0214] (1) Add a certain amount of fat extract D to water and stir until a uniform emulsion is formed;
[0215] (2) slowly adding fat extract C into the above-mentioned uniform emulsion and mixing;
[0216] (3) The adipose decellularized biomaterial E is obtained after injection molding and freeze drying.
[0217] Further, the freeze-drying process conditions are: pre-freezing for 1-24 hours and freeze-drying for 24-72 hours.
[0218] Tissue repair materials
[0219] The adipose decellularized biological material of the present invention is prepared by freeze drying, and the active protein factors in the material can be stored for a long time without losing activity.
[0220] In practical applications, the adipose decellularized biomaterial described in the present invention can be mixed with solutions such as physiological saline, PBS buffer, glycerol, polyethylene glycol, etc. in a certain mass ratio. Mixing with these materials can give the adipose decellularized biomaterial described in the present invention corresponding fluidity, so that it can be injected into irregular tissue defect sites, facilitating clinical use.
[0221] Therefore, another aspect of the present invention also includes a composition of adipose decellularized biomaterials. The adipose decellularized biomaterial of the present invention can be mixed with a carrier to form an injectable tissue repair material with fluidity.
[0222] Medical materials and administration methods
[0223] Since the biomaterial of the present invention has excellent activity in promoting tissue repair and enhancing fibrin regeneration, the biomaterial of the present invention and tissue repair materials containing the biomaterial of the present invention as a main active ingredient can be used for soft tissue repair and / or plastic filling.
[0224] The tissue repair material of the present invention comprises a safe and effective amount of the biomaterial of the present invention and a pharmaceutically acceptable excipient or carrier. "Safe and effective amount" means an amount of the material sufficient to significantly improve the condition without causing serious side effects. The therapeutically effective amount is determined based on the subject's age, condition, and duration of treatment. Typically, the tissue repair material contains 1-2000 mg of the biomaterial of the present invention per dose, more preferably 10-1000 mg per dose.
[0225] The term "pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "Compatibility" herein refers to the ability of the components of the composition to blend with the biomaterial of the present invention, and with each other, without significantly reducing the efficacy of the biomaterial. Examples of pharmaceutically acceptable carriers include sugars (e.g., glucose, sucrose, lactose, etc.), gelatin, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween), wetting agents (e.g., sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0226] There is no particular limitation on the administration method of the biomaterial or medical or medical cosmetic material of the present invention. Representative administration methods include (but are not limited to): parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
[0227] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0228] The dosage forms of the biomaterial of the present invention for topical administration include gels, ointments, powders, patches, sprays and inhalants. The active ingredient is mixed with a physiologically acceptable carrier and any preservatives and buffers under sterile conditions.
[0229] The biomaterials and pharmaceutically acceptable salts thereof of the present invention can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents.
[0230] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.
[0231] When using a pharmaceutical composition, a safe and effective amount of the biomaterial of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.
[0232] The main advantages of the present invention include:
[0233] (1) During the fat decellularization process, the present invention first extracts a fat-rich active protein mixture through an additive-free method to ensure that it is cell-free, sterile, and virus-free, thereby avoiding the removal and contamination of these active protein factors by chemical or biological reagents during the decellularization process. The obtained fat decellularized biomaterial retains a large amount of active protein factors compared to known processes.
[0234] (2) The adipose decellularized biomaterial of the present invention retains the active protein factors of human tissue itself, and is more active and biosafe than recombinant active protein factors.
[0235] (3) The active protein in the adipose decellularized biomaterial of the present invention is evenly dispersed in the biomaterial through a process and adheres to the collagen fibers in the biomaterial. During use, the active protein can be slowly released in the damaged tissue area (can remain effective for 3 to 6 months), and can accurately promote angiogenesis in the trauma site for a long time, thereby achieving the goal of repairing tissue function.
[0236] (4) The freeze-dried adipose decellularized biomaterial has a porous structure, can be preserved for a long time, and is easy to realize industrial production.
[0237] (5) The adipose decellularized biomaterial of the present invention does not introduce exogenous proteins or materials and has good biocompatibility with human tissues.
[0238] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which no specific conditions are specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0239] Example 1:
[0240] The present invention prepares a fat decellularized biomaterial according to the following method, which includes the steps of preparing fat primary extract A and fat primary extract B, and the step of preparing the fat decellularized biomaterial.
[0241] a. Preparation of primary fat extract A and primary fat extract B
[0242] (a1) Adipose tissue was obtained from six healthy women undergoing conventional liposuction (mean age 31 years, range 24-36 years). After local anesthesia with tumescent fluid injection, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) connected to a 20 mL syringe was used for radial aspiration under artificial negative pressure. The obtained fat was then placed upright and rested. After removal of the tumescent fluid, the tissue was rinsed three times with normal saline.
[0243] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g and 4° C. for 3 minutes to obtain a layered mixture.
[0244] (a3) removing the upper oil layer and the lower water layer from the separated mixture, and collecting the middle layer (i.e., the fat layer containing fat cells).
[0245] (a4) The intermediate layer is mechanically emulsified by repeatedly pushing and hitting the intermediate layer 30 times at a constant speed using two 10 ml syringes connected to a three-way pipe to obtain a mechanically emulsified fat mixture (also called nanofat).
[0246] (a5) The mechanically emulsified fat mixture is frozen in a -80°C freezer and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200 g for 5 minutes at 4°C to obtain a layered mixture. The layered mixture is divided into four layers: a first layer being an oil layer, a second layer being a residual adipose tissue layer, a third layer being a liquid layer, and a fourth layer being a cell / tissue fragment sedimentation layer.
[0247] (a6) removing the oil layer and the cell / tissue debris sediment layer, taking the liquid layer, namely the primary fat extract A, and taking the residual adipose tissue layer (solid layer), namely the primary fat extract B.
[0248] (a7) The obtained primary fat extract A was sterilized by filtration through a 0.22 μm filter to sterilize and remove any living cells, thereby obtaining a cell-free fat extract C (CEFFE). The aliquots were frozen and stored at −20° C. and thawed at 4° C. before use.
[0249] b. Preparation of adipose decellularized biomaterials
[0250] (b1) The primary fat extract B was emulsified using a homogenizer at 10,000 rpm for 2 minutes, and centrifuged at 4,000 rpm for 10 minutes to separate the oil layer and obtain the solid content.
[0251] (b2) adding the solid contents obtained in step (b1) into a 0.5% / 4% peracetic acid / ethanol disinfectant at a mass ratio of 1:10 and shaking for 4 hours. After treatment, the liquid layer is discarded, and the solid contents are shaken and washed with a PBS solution and purified water in turn to obtain solid contents.
[0252] (b3) The solid contents obtained in step (b2) were added to 1% Triton X-100 at a mass ratio of 1:10 and shaken for 72 hours, with the solution being changed once every 8 hours. The liquid layer after treatment was discarded, and the solid contents were shaken and washed with PBS solution and purified water in turn to obtain solid contents.
[0253] (b4) The solid content obtained in step (b3) was added to ether at a mass ratio of 1:6 and shaken for 3 hours, or added to isopropyl alcohol at a mass ratio of 1:10 and shaken for 3 hours. After treatment, the liquid layer was discarded and the mixture was washed with PBS solution and purified water in sequence to obtain a solid content. The solid contents obtained using isopropyl alcohol and ether, respectively, are shown in Figure 1.
[0254] (b5) The solid contents obtained in step (b4) were added to 20 times the mass of purified water and stirred until a homogeneous emulsion (acellular fat extract D) was formed. The fat extract C solution was then slowly added to the homogeneous emulsion and mixed thoroughly. The emulsion was then poured into a mold, pre-frozen at -80°C for 12 hours, and freeze-dried for 48 hours to obtain a cell-free adipose biomaterial.
[0255] Example 2:
[0256] The present invention prepares a decellularized fat biomaterial according to the following method, which includes the steps of preparing primary fat extract A and primary fat extract B, and preparing the decellularized fat biomaterial. Example 2 differs from Example 1 in that, in step (a4), the intermediate layer is emulsified using a homogenizer at 12,000 rpm for 3 minutes to obtain a mechanically emulsified fat mixture.
[0257] a. Preparation of primary fat extract A and primary fat extract B
[0258] (a1) Adipose tissue was obtained from six healthy women undergoing conventional liposuction (mean age 31 years, range 24-36 years). After local anesthesia with tumescent fluid injection, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) connected to a 20 mL syringe was used for radial aspiration under artificial negative pressure. The obtained fat was then placed upright and rested. After removal of the tumescent fluid, the tissue was rinsed three times with normal saline.
[0259] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g and 4° C. for 3 minutes to obtain a layered mixture.
[0260] (a3) removing the upper oil layer and the lower water layer from the separated mixture, and collecting the middle layer (i.e., the fat layer containing fat cells).
[0261] (a4) The intermediate layer was emulsified using a homogenizer at 12,000 rpm for 3 minutes to obtain a mechanically emulsified fat mixture.
[0262] (a5) The mechanically emulsified fat mixture is frozen in a -80°C freezer and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200 g for 5 minutes at 4°C to obtain a layered mixture. The layered mixture is divided into four layers: a first layer being an oil layer, a second layer being a residual adipose tissue layer, a third layer being a liquid layer, and a fourth layer being a cell / tissue fragment sedimentation layer.
[0263] (a6) removing the oil layer and the cell / tissue debris sediment layer, taking the liquid layer, namely the primary fat extract A, and taking the residual adipose tissue layer (solid layer), namely the primary fat extract B.
[0264] (a7) The obtained primary fat extract A was sterilized by filtration through a 0.22 μm filter to sterilize and remove any living cells, thereby obtaining a cell-free fat extract C (CEFFE). The aliquots were frozen and stored at −20° C. and thawed at 4° C. before use.
[0265] b. Preparation of adipose decellularized biomaterials
[0266] (b1) The primary fat extract B was emulsified using a homogenizer at 10,000 rpm for 2 minutes, and centrifuged at 4,000 rpm for 10 minutes to separate the oil layer and obtain the solid content.
[0267] (b2) adding the solid contents obtained in step (b1) into a 0.5% / 4% peracetic acid / ethanol disinfectant at a mass ratio of 1:10 and shaking for 4 hours. After treatment, the liquid layer is discarded, and the solid contents are shaken and washed with a PBS solution and purified water in turn to obtain solid contents.
[0268] (b3) The solid contents obtained in step (b2) were added to 1% Triton X-100 at a mass ratio of 1:10 and shaken for 72 hours, with the solution being changed every 8 hours. The liquid layer was discarded after treatment, and the solid contents were washed with PBS solution and purified water by shaking to obtain solid contents.
[0269] (b4) The solid content obtained in step (b3) was added to ether at a mass ratio of 1:6 and shaken for 3 hours. After treatment, the liquid layer was discarded and the mixture was washed with PBS solution and purified water in sequence to obtain solid content.
[0270] (b5) The solid contents obtained in step (b4) were added to 20 times the mass of purified water and stirred until a homogeneous emulsion (acellular fat extract D) was formed. The fat extract C solution was then slowly added to the homogeneous emulsion and mixed thoroughly. The emulsion was then poured into a mold, pre-frozen at -80°C for 12 hours, and freeze-dried for 48 hours to obtain a cell-free adipose biomaterial.
[0271] Comparative Example 1:
[0272] The difference between Comparative Example 1 and Example 1 is that only the cell-free fat extract C is prepared. The method includes the steps of preparing the primary fat extract A and the step of preparing the cell-free fat extract C.
[0273] a. Preparation of primary fat extract A and cell-free fat extract C
[0274] (a1) Adipose tissue was obtained from six healthy women undergoing conventional liposuction (mean age 31 years, range 24-36 years). After local anesthesia with tumescent fluid injection, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) connected to a 20 mL syringe was used for radial aspiration under artificial negative pressure. The obtained fat was then placed upright and rested. After removal of the tumescent fluid, the tissue was rinsed three times with normal saline.
[0275] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g and 4° C. for 3 minutes to obtain a layered mixture.
[0276] (a3) removing the upper oil layer and the lower water layer from the separated mixture, and collecting the middle layer (i.e., the fat layer containing fat cells).
[0277] (a4) Mechanically emulsify the intermediate layer by repeatedly pushing and hitting the intermediate layer 30 times at a constant speed using two 10 ml syringes connected to a three-way pipe to obtain a mechanically emulsified fat mixture.
[0278] (a5) The mechanically emulsified fat mixture is frozen in a -80°C freezer and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200 g for 5 minutes at 4°C to obtain a layered mixture. The layered mixture is divided into four layers: a first layer being an oil layer, a second layer being a residual adipose tissue layer, a third layer being a liquid layer, and a fourth layer being a cell / tissue fragment sedimentation layer.
[0279] (a6) Remove the oil layer and the cell / tissue debris sediment layer, and take the liquid layer, which is the primary fat extract A.
[0280] (a7) The obtained primary fat extract A is sterilized by filtration through a 0.22 μm filter to sterilize and remove any living cells, thereby obtaining a cell-free fat extract C (CEFFE). The extract is then injected into a mold, pre-frozen at -80°C for 12 hours, and freeze-dried for 48 hours to obtain a cell-free fat biomaterial.
[0281] Comparative Example 2:
[0282] In this comparative example 2, a fat decellularized biomaterial was prepared according to the following method. The difference from Example 1 is that no acellular fat extract C was prepared. The method includes the steps of preparing a fat primary extract B and preparing a fat decellularized biomaterial.
[0283] a. Preparation of primary fat extract B
[0284] (a1) Adipose tissue was obtained from six healthy women undergoing conventional liposuction (mean age 31 years, range 24-36 years). After local anesthesia with tumescent fluid injection, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) connected to a 20 mL syringe was used for radial aspiration under artificial negative pressure. The obtained fat was then placed upright and rested. After removal of the tumescent fluid, the tissue was rinsed three times with normal saline.
[0285] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g and 4° C. for 3 minutes to obtain a layered mixture.
[0286] (a3) removing the upper oil layer and the lower water layer from the separated mixture, and collecting the middle layer (i.e., the fat layer containing fat cells).
[0287] (a4) Mechanically emulsify the intermediate layer by repeatedly pushing and hitting the intermediate layer 30 times at a constant speed using two 10 ml syringes connected to a three-way pipe to obtain a mechanically emulsified fat mixture.
[0288] (a5) The mechanically emulsified fat mixture is frozen in a -80°C freezer and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200 g for 5 minutes at 4°C to obtain a layered mixture. The layered mixture is divided into four layers: a first layer being an oil layer, a second layer being a residual adipose tissue layer, a third layer being a liquid layer, and a fourth layer being a cell / tissue fragment sedimentation layer.
[0289] (a6) removing the oil layer and the cell / tissue debris sediment layer, and taking the residual adipose tissue layer (solid layer), i.e., the primary adipose extract B.
[0290] b. Preparation of adipose decellularized biomaterials
[0291] (b1) The primary fat extract B was emulsified using a homogenizer at 10,000 rpm for 2 minutes, and centrifuged at 4,000 rpm for 10 minutes to separate the oil layer and obtain the solid content.
[0292] (b2) adding the solid contents obtained in step (b1) into a 0.5% / 4% peracetic acid / ethanol disinfectant at a mass ratio of 1:10 and shaking for 4 hours. After treatment, the liquid layer is discarded, and the solid contents are shaken and washed with a PBS solution and purified water in turn to obtain solid contents.
[0293] (b3) The solid contents obtained in step (b2) were added to 1% Triton X-100 at a mass ratio of 1:10 and shaken for 72 hours, with the solution being changed once every 8 hours. The liquid layer after treatment was discarded, and the solid contents were shaken and washed with PBS solution and purified water in turn to obtain solid contents.
[0294] (b4) The solid content obtained in step (b3) was added to ether at a mass ratio of 1:6 and shaken for 3 hours. After treatment, the liquid layer was discarded and the mixture was washed with PBS solution and purified water in sequence to obtain solid content.
[0295] (b5) The solid content obtained in step (b4) was added to 20 times the mass of purified water and stirred until a uniform emulsion (acellular fat extract D) was formed. The emulsion was poured into a mold, pre-frozen at -80 degrees Celsius for 12 hours, and freeze-dried for 48 hours to obtain a cell-free adipose biomaterial.
[0296] Comparative Example 3:
[0297] In this comparative example 3, a fat decellularized biomaterial was prepared according to the following method. The difference from Example 1 is that no acellular fat extract C was prepared, and vascular endothelial growth factor (VEGF) was added during step b. preparing the fat decellularized biomaterial. The method includes the steps of preparing the primary fat extract B and adding vascular endothelial growth factor (VEGF) to prepare the fat decellularized biomaterial.
[0298] a. Preparation of primary fat extract B
[0299] (a1) Adipose tissue was obtained from six healthy women undergoing conventional liposuction (mean age 31 years, range 24-36 years). After local anesthesia with tumescent fluid injection, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) connected to a 20 mL syringe was used for radial aspiration under artificial negative pressure. The obtained fat was then placed upright and rested. After removal of the tumescent fluid, the tissue was rinsed three times with normal saline.
[0300] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g and 4° C. for 3 minutes to obtain a layered mixture.
[0301] (a3) removing the upper oil layer and the lower water layer from the separated mixture, and collecting the middle layer (i.e., the fat layer containing fat cells).
[0302] (a4) Mechanically emulsify the intermediate layer by repeatedly pushing and hitting the intermediate layer 30 times at a constant speed using two 10 ml syringes connected to a three-way pipe to obtain a mechanically emulsified fat mixture.
[0303] (a5) The mechanically emulsified fat mixture is frozen in a -80°C freezer and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200 g for 5 minutes at 4°C to obtain a layered mixture. The layered mixture is divided into four layers: a first layer being an oil layer, a second layer being a residual adipose tissue layer, a third layer being a liquid layer, and a fourth layer being a cell / tissue fragment sedimentation layer.
[0304] (a6) removing the oil layer and the cell / tissue debris sediment layer, and taking the residual adipose tissue layer (solid layer), i.e., the primary adipose extract B.
[0305] b. Preparation of adipose decellularized biomaterials
[0306] (b1) The primary fat extract B was emulsified using a homogenizer at 10,000 rpm for 2 minutes, and centrifuged at 4,000 rpm for 10 minutes to separate the oil layer and obtain the solid content.
[0307] (b2) adding the solid contents obtained in step (b1) into a 0.5% / 4% peracetic acid / ethanol disinfectant at a mass ratio of 1:10 and shaking for 4 hours. After treatment, the liquid layer is discarded, and the solid contents are shaken and washed with a PBS solution and purified water in turn to obtain solid contents.
[0308] (b3) The solid contents obtained in step (b2) were added to 1% Triton X-100 at a mass ratio of 1:10 and shaken for 72 hours, with the solution being changed once every 8 hours. The liquid layer after treatment was discarded, and the solid contents were shaken and washed with PBS solution and purified water in turn to obtain solid contents.
[0309] (b4) The solid content obtained in step (b3) was added to ether at a mass ratio of 1:6 and shaken for 3 hours. After treatment, the liquid layer was discarded and the mixture was washed with PBS solution and purified water in sequence to obtain solid content.
[0310] (b5) The solid content obtained in step (b4) was added to 20 times the weight of purified water and stirred until a homogeneous emulsion (acellular adipose extract D) was formed. The VEGF solution was then slowly added to the homogeneous emulsion and mixed thoroughly. The emulsion was then poured into a mold, pre-frozen at -80°C for 12 hours, and freeze-dried for 48 hours to obtain a decellularized adipose biomaterial.
[0311] Test Example 1
[0312] The materials of Example 1 and Comparative Examples 1-3 were subjected to in vitro degradation tests according to the method of GB / T 16886.13, and the protein content in the extract was measured to reflect the protein release of the materials. The specific operation was as follows:
[0313] The sample was dried in a vacuum oven at 25°C to constant weight. 20 mg of the sample was weighed and placed in a 50 ml polypropylene centrifuge tube. 10 ml of PBS buffer solution was added. The tube was tightly capped and placed in a 37°C constant temperature incubator for 14 days. The tube was centrifuged at 7000 r / min for 5 minutes. The supernatant was aspirated and the protein content in the extract was determined by the BCA method.
[0314] The protein release of the materials in the examples and comparative examples is shown in Table 1. The protein release concentrations of Examples 1, 2 and 3 are relatively high, especially in Example 2. At the same time, Examples 1 and 2 retain the active proteins of human tissues themselves and do not introduce exogenous proteins, which are safer than Comparative Example 2.
[0315] Table 1 Material protein release
[0316] Test Example 2
[0317] The materials of Examples 1, 2 and Comparative Examples 2, 3 were prepared with physiological saline at a concentration of 6 mg / ml, drawn into a syringe, and subcutaneous injections of 0.2 ml were performed on mice. Samples were collected at 2 weeks, 1 month, and 3 months.
[0318] Material retention rate: Weigh the sampled material and place it into a 1ml sealed syringe filled with PBS buffer. Use a 10μl pipette to draw up the rising solution to the initial scale. Calculate and record the mass retention rate and the retention rate of the material at each sampling point.
[0319] Mass retention rate (%) = mass of material at the time of collection / initial mass of material × 100%
[0320] Volume retention rate (%) = volume of material at the time of collection / initial volume of material × 100%
[0321] As shown in Tables 2-3, Example 1, Example 2, and Comparative Example 3 showed significantly better retention of material mass and volume at 2 weeks, 1 month, and 3 months after implantation compared to Comparative Example 2. Combined with the results of Test Example 1, we believe that the adipose-derived biomaterial prepared by the present invention can achieve sustained release of active proteins in the subcutaneous tissue region after implantation, promoting tissue regeneration.
[0322] Compared with Example 1, Example 2 replaces the repeated uniform pushing and beating of the injection syringe connected to the three-way tube in step (a4) with emulsification by a homogenizer. On the one hand, the concentration of fat active protein in the final fat decellularized biomaterial is higher, and at the same time, the structure of the active protein and the biomaterial particles is closer, so the retention rate is higher. This shows that the present invention can achieve a higher retention rate of fat decellularized biomaterial by adjusting the process to ensure the long-term effect of promoting tissue regeneration.
[0323] Histological observation: The removed material was stained with hematoxylin and eosin (H&E). The chromatin in the cell nucleus and the nucleic acid in the cytoplasm appeared purple, and the proteins in the cytoplasm and extracellular matrix appeared red or pink. The results are shown in Figure 2.
[0324] At 2 weeks, fibroblast proliferation (black arrows) and fibrosis were observed around each material, with a small amount of adipocyte infiltration (grey arrows); at 1 month, the material showed some degradation, with obvious proliferation of fibrosis, fibroblasts, and collagen fibers around the material, and increased adipocyte regeneration; by 3 months, the material showed significant degradation, and adipocyte regeneration further increased. The number of adipocytes in the materials of Examples 1 and 2 was significant and aggregated, accompanied by the generation of new blood vessel cells (red arrows), while the number and degree of adipocyte aggregation in Comparative Example 2 were lower than those in Examples 1 and 2. Although Comparative Example 3 added VEGF, which had a positive effect on the mass and volume retention of the material after implantation, its effect on adipocyte regeneration was weaker than that of the examples. This shows that the adipose decellularized biomaterial prepared by the present invention has excellent effects in promoting fibroblast proliferation, adipose tissue regeneration, and angiogenesis.
[0325] Table 2 Material quality retention rate data
[0326] Table 3 Material volume retention rate data
[0327] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A fat decellularized biomaterial, characterized in that: The adipose decellularized biomaterial is prepared by the following method, which comprises the following steps: (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue; (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer; (3) emulsifying the intermediate layer to obtain an emulsified fat mixture; (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B; (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C; (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D; (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.
2. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (3), the emulsification is mechanical emulsification; wherein the mechanical emulsification is performed by repeatedly blowing with a syringe (such as blowing 20-200 times, preferably 20-150 times, more preferably 20-100 times, and more preferably 30-50 times).
3. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (3), the emulsification includes breaking and emulsifying by a tissue homogenizer.
4. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (4), after centrifugation, the emulsified fat mixture is divided into four layers, the first layer is an oil layer, the second layer is a residual fat tissue layer (i.e., an intermediate solid layer), the third layer is a liquid layer (i.e., an intermediate liquid layer), and the fourth layer is a cell / tissue fragment precipitation layer.
5. The adipose decellularized biomaterial according to claim 1, characterized in that: The step (6) comprises: (6a) emulsifying the primary fat extract B and performing post-processing to obtain a solid content; (6b) sterilizing the solid contents obtained in step (6a), and post-treating the solid contents; (6c) decellularizing the solid contents obtained in step (6b), and post-processing to obtain solid contents; (6d) defatting the solid contents obtained in step (6c), and post-treating to obtain solid contents; (6e) diluting the solid content obtained in step (6d) to obtain a cell-free fat extract D.
6. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the emulsification treatment includes homogenizing and emulsifying with a homogenizer, the emulsification treatment also includes a step of centrifugally separating the oil layer, and the emulsification treatment includes one or more features selected from the following group: (1) The rotation speed of the homogenizer is 5000-15000 r / min; (2) The emulsification time is 0.5-15 min; (3) the centrifugation is performed at 1000-8000 r / min; (4) The centrifugation time is 2-20 min.
7. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the disinfection treatment includes mixing with a disinfectant, and discarding the liquid layer after oscillation treatment; and the disinfection treatment also includes one or more features selected from the following group: (1) The disinfectant is a mixed solution of peracetic acid and ethanol, the concentration of the peracetic acid is 0.05-3%, and the concentration of the ethanol is 1-24%; (2) The mass ratio of the solid content obtained after emulsification to the disinfectant is 1:1 to 1:20; (3) The shaking treatment time is 0.5-6h.
8. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the decellularization treatment includes mixing with a decellularization agent, and discarding the liquid layer after oscillation treatment; and the decellularization treatment also includes one or more features selected from the following group: (1) The decellularizing agent is selected from SDS, TritonX-100, sodium deoxycholate, or a combination thereof; (2) the concentration of the decellularizing agent is 0.2-5%; (3) The mass ratio of the solid content obtained after disinfection to the decellularizing agent is 1:1 to 1:20; (4) The shaking treatment time is 12-96 hours.
9. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the degreasing treatment includes mixing with a degreasing agent, and discarding the liquid layer after oscillation treatment; and the degreasing treatment also includes one or more characteristics selected from the following group: (1) The degreasing agent is selected from isopropyl alcohol, ethanol, ether, or a combination thereof. (2) the mass ratio of the solid content obtained after decellularization to the degreasing agent is 1:1 to 1:20; (3) The shaking treatment time is 0.5-24h.
10. The adipose decellularized biomaterial according to claim 1, characterized in that: The step (7) comprises the following steps: (7a) providing a cell-free fat extract D in the form of an emulsion; (7b) adding the fat extract C to the emulsion obtained in step (7a) and mixing; (7c) The adipose decellularized biomaterial is obtained after freeze drying.
11. A method for preparing adipose decellularized biomaterial according to claim 1, characterized in that: The method comprises the following steps: (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue; (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer; (3) emulsifying the intermediate layer to obtain an emulsified fat mixture; (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B; (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C; (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D; (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.
12. A tissue repair material, characterized in that: The tissue repair material comprises the adipose decellularized biomaterial as claimed in claim 1.
13. The use of the adipose decellularized biomaterial according to claim 1, characterized in that: Used to prepare a medical material or a medical cosmetic material, wherein the medical material is used for soft tissue repair and the medical cosmetic material is used for plastic surgery filling.
14. A method for soft tissue repair, comprising administering the adipose decellularized biomaterial of claim 1 to a subject in need thereof.
15. A method for plastic surgery, comprising administering the adipose decellularized biomaterial according to claim 1 to a subject in need thereof.
Citation Information
Patent Citations
Preparation method and application of injectable allogeneic adipose acellular matrix particles
CN108478868A
Biological material taken from adipose tissue, and preparation method and application of biological material
CN110496241A
Fat extract without additive components as well as preparation method and application of fat extract
CN112386528A
Cell-free fat extracts for improving aging and promoting skin rejuvenation
CN114903920A
Cell-free fat extracts for treatment of vaginal atrophy
CN115702907A
